Skip to main content
SAMJIN PHARMACEUTICAL CO.,LTD logo

SAMJIN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 005500 ISIN · KR7005500004 KO Manufacturing
Open in API
Filings indexed 253 across all filing types
Latest filing 2022-08-30 Major Shareholding Noti…
Country KR South Korea
Listing KO 005500

About SAMJIN PHARMACEUTICAL CO.,LTD

https://www.samjinpharm.co.kr/

Samjin Pharmaceutical Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of medicines. The company's portfolio includes a wide range of over-the-counter (OTC) and prescription drugs, offered in various formulations such as oral, drop, and injectable forms. Notable products include the analgesic Gevorin, the antiplatelet agent Plavix, and the hypercholesterolemia treatment Newstatin-R. A central part of its strategy is a strong commitment to R&D, focusing on creating innovative new drugs to address diseases with high unmet medical needs. The company actively develops novel therapeutics for severe conditions, including cardiovascular, respiratory, and gastrointestinal diseases, with the goal of becoming a global pharmaceutical innovator.

Recent filings

Filing Released Lang Actions
타법인주식및출자증권취득결정
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from Samjin Pharmaceutical regarding the acquisition of shares in another company (AriBio). It details the acquisition amount, purpose, and board approval, which is a standard disclosure for M&A or strategic investment activity. Since it involves the acquisition of shares in another entity, it falls under the M&A Activity category (TAR).
2022-08-30 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form required by the Financial Supervisory Service (FSS) in South Korea when a major shareholder or executive changes their stake in a company. Since the document details a change in share ownership by a major shareholder (Hana Pharm Co., Ltd. in Samjin Pharm Co., Ltd.), it falls under the category of 'Major Shareholding Notification' (MRQ).
2022-08-30 Korean
[기재정정]타법인주식및출자증권취득결정
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from Samjin Pharmaceutical regarding the acquisition of shares in another company (AriBio). It details the acquisition, the number of shares, the purpose of the investment, and financial information about the target company. This type of disclosure, specifically regarding 'Acquisition of shares and securities of other corporations' (타법인주식및출자증권취득결정), is a standard regulatory announcement in the Korean market (DART system). Since it does not fit into specific categories like M&A (which usually implies a full takeover or merger) or capital changes, it is best classified as a general Regulatory Filing (RNS).
2022-08-30 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. This specific type of filing is used to report significant changes in share ownership (often referred to as a 5% rule filing or major shareholding notification). It details the reporter (Choi Sung-ju), the issuer (Samjin Pharmaceutical), and changes in shareholding status and collateral agreements. This falls under the 'Major Shareholding Notification' category.
2022-08-26 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in South Korea. It details changes in share ownership by a major shareholder (Hana Pharm Co., Ltd.) in Samjin Pharm Co., Ltd. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) as it tracks changes in significant share ownership levels and insider/major shareholder holdings.
2022-08-17 Korean
반기보고서 (2022.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for Samjin Pharmaceutical Co., Ltd., covering the period from January 1, 2022, to June 30, 2022. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2022
2022-08-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.